About Theragenics
Theragenics is a Healthcare company based in Buford (United States) founded in 1981, and was acquired by Juniper Investment Company in August 2013. Manufacturer of surgical products and brachytherapy devices. Theragenics has raised $9.44 million across 3 funding rounds from investors including Wingspire Capital and Juniper Investment Company. Theragenics has completed 3 acquisitions, including CP Medical, GaltNeedleTech and NeedleTech. Its chief executive, as recorded, is Francis Tarallo. Theragenics offers products and services including TheraSeed, AgX100, Cesium-131, and Pursue Hydrophilic Guidewire. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is Theragenics Corp. Its competitors include Koya Medical, Sensus Healthcare and CivaTech Oncology; 3 of its 3 listed competitors have raised funding.
Company details
Theragenics Corporation is a medical device company that focuses on the cancer treatment and surgical markets. It manufactures and markets brachytherapy seeding devices that are used in the minimally invasive treatment of localized prostate cancer and of early-stage breast cancer. Its surgical products Also manufactures and distributes surgical products especially wound closure devices, needles and other surgical products. Clients include equipment manufacturers, a network of distributors, and directly to healthcare providers and group purchasing organizations. Has acquired the U.S. and Canadian seed business of Eckert Ziegler BEBIG.
- Headquarters Buford, United States
- Stage Acquired
- SectorsHealthcare
- Website theragenics.com
- Social LinkedIn X Facebook YouTube
- Acquired by Juniper Investment Company (Aug 2013)
- Legal Name Theragenics Corp
- Total Equity Funding$9.44M (USD)
in 3 rounds
- Latest Funding Round$40M (USD), Debt – Conventional
Nov 2021
- InvestorsWingspire Capital
& 1 more
- Investments & AcquisitionsCP Medical
& 2 more
- Acquired byJuniper Investment Company
(Aug 2013)
Products & Services of Theragenics
Theragenics offers a comprehensive portfolio of products and services, including TheraSeed, AgX100, Cesium-131, and Pursue Hydrophilic Guidewire.
Palladium-103 seeds for prostate cancer treatment.
Iodine-125 implants for localized cancer therapies.
Radioisotope for seamless global delivery solutions.
Guidewire for improving vascular access outcomes.
Apps and channels of Theragenics
its YouTube channel Theragenics has 20 subscribers and 5 videos.
Videos from Theragenics
The most watched videos on Theragenics's YouTube channel, Theragenics (20 subscribers). Click a video to play it here.
More on Theragenics.
Funding Insights of Theragenics
Theragenics has successfully raised a total of $9.44M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $40 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.44M
- Total Rounds 3
- Last Round Debt – Conventional — $40M
- First Round $6.25M
(May 2005)
- Investors Count 1
All 3 funding rounds of Theragenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $40M | Debt – Conventional | – | – | |
| Aug 2006 | $3.19M | Series A | – | – | – |
| May 2005 | $6.25M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Theragenics
Theragenics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Wingspire Capital and Juniper Investment Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides customized loans and financing to middle market firms worldwide. | 2019 | wingspirecapital.com | Alpharetta, United States | |
Invests in under-followed small cap US companies and engages management for strategy execution. | 2007 | juniperfunds.com | New York, United States |
Investor details for Theragenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Theragenics
2 people are tracked at Theragenics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Francis Tarallo | CEO | Leadership |
John Lobdell | CEO & Director | Leadership |
Complete people profiles for Theragenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Theragenics
Theragenics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include CP Medical, GaltNeedleTech and NeedleTech.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of insurance broking services for corporate, commercial, and personal clients | needletech.com | North Attleborough, United States | 1991 | Jul 2008 | $47.8M | |
Medical devices manufacturer | galtmedical.com | Attleboro, United States | 1991 | Aug 2006 | $31.9M | |
Manufactures private label and branded surgical solutions for medical and veterinary markets | cpmedical.com | Norcross, United States | 2001 | Apr 2005 | $25.28M |
Complete acquisition details for Theragenics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Theragenics
7 dated milestones of Theragenics across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Theragenics is founded.
- Acquisition Acquires CP Medical.
- Funding First funding round of $6.2M.
- Acquisition Acquires GaltNeedleTech.
- Acquisition Acquires NeedleTech.
- Exit Acquired by Juniper Investment Company.
- Funding Latest funding round, Debt – Conventional, of $40.0M.
Competitors of Theragenics
Theragenics has 3 listed competitors in our database, 3 of them funded. They include Koya Medical, Sensus Healthcare and CivaTech Oncology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| koyamedical.com | 2018 | Oakland, United States | $37.02M | 122 | Provider of smart wearable compression technology for lymphedema and venous diseases | |
| sensushealthcare.com | 2010 | Boca Raton, United States | $12.24M | 42 | Non-invasive skin cancer treatments are developed and marketed. | |
| civatechoncology.com | 2006 | Durham, United States | $12.4M | Polymer-based devices for low-dose brachytherapy in solid tumors are provided. |
Detailed competitors of Theragenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Theragenics
The website of Theragenics (theragenics.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 8.8% vs previous month
Websites whose visitors overlap most with Theragenics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| carbonmed.com | 100% | 2.2K | #8,575,514 | View details | |
| izimed.com | 84% | 3.8K | #5,149,944 | View details |
Top companies in Oncology
3 companies that operate in the same segment as Theragenics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Theragenics
Complete news archive for Theragenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Theragenics
Theragenics was founded in 1981 and raised its 1st funding round 24 years after it was founded.
Theragenics is headquartered in Buford, United States. It is registered at Buford, Georgia, United States.
Francis Tarallo is the CEO of Theragenics, as recorded in our data.
Theragenics is a funded company, having raised a total of $9.44M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.25M, raised on May 2005.
Theragenics Corporation is a medical device company that focuses on the cancer treatment and surgical markets. It manufactures and markets brachytherapy seeding devices that are used in the minimally invasive treatment of localized prostate cancer and of early-stage breast cancer. Its surgical products Also manufactures and distributes surgical products especially wound closure devices, needles and other surgical products. Clients include equipment manufacturers, a network of distributors, and directly to healthcare providers and group purchasing organizations. Has acquired the U.S. and Canadian seed business of Eckert Ziegler BEBIG.
Theragenics's top competitors include Koya Medical, Sensus Healthcare and CivaTech Oncology.
Theragenics offers TheraSeed, AgX100, Cesium-131, and Pursue Hydrophilic Guidewire.
Theragenics has made 3 acquisitions, including CP Medical, GaltNeedleTech, and NeedleTech.
Theragenics has 2 investors. Key investors include Wingspire Capital, and Juniper Investment Company.
Theragenics operates through Theragenics Corp.
Yes. Theragenics was acquired by Juniper Investment Company in August 2013.